Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation
Cancer, 07/31/2012
Scosyrev E et al. – If the pre–prostate–specific antigen (PSA) era rates were present in the modern US population, then the total number of men presenting with metastatic (M1) prostate cancer (PC) would be approximately 3 times greater than the number actually observed.



